Glooko is a healthcare technology company which offers a diabetes management platform to healthcare providers, patients, and pharmaceutical companies. The platform is designed to integrate with hundreds of diabetes devices to gather and analyze patient data. Through comprehensive data centralization and analytical tools, Glooko aims to enhance diabetes management and facilitate clinical research in the field. This company was founded by Yogen Dalal, Sundeep Madra, and Chamath Palihapitiya in 2010 and is headquartered in Palo Alto, CA.
Glooko is privately held and not traded on public markets, so pre-IPO investments are available only to accredited investors.
If you’re already accredited and have completed Forge’s verification, you can visit our marketplace to review and invest in private companies ahead of an IPO.
If you haven’t yet completed your accredited investor verification with Forge, you can start that process now to unlock access to new private-company offerings.
Can you sell shares of Glooko before it goes public?
Yes, subject to any contractual or corporate transfer restrictions, it is possible to list your shares to sell while Glooko is still private. If you’re considering selling, you can register today for free to get started. Once registered, you can evaluate pricing insights and market activity to inform your decision, then post your shares for sale and set the terms, like quantity and price—all directly through our platform.
If you’d like additional guidance at any point, Forge private market specialists are available to help. For a step-by-step overview, check out our seller’s guide.
What is the pre-IPO value of my Glooko shares?
To explore the value of your Glooko shares, create a free account to access Forge’s marketplace. Once inside, you’ll find several pricing insights to help guide your decision—these include historical transaction data, a live order book showing current buy and sell interest, and Forge Price™, a derived, indicative price based on recent transactions, investor activity, and other relevant market data.
These insights can help you determine a price you’re comfortable with if you choose to sell your shares. If you’d like additional guidance along the way, Forge private market specialists are available to help. You can also review our seller’s guide for a step-by-step overview.
Is Glooko a publicly traded company?
Glooko is a private company and not publicly traded.
If you’re interested in buying or selling shares in private companies, you can register with Forge today for free to explore available opportunities. Once registered, you’ll gain access to our marketplace, where you can view active buy and sell interest, evaluate pricing signals and take action directly through the platform.
To learn more about Glooko potential IPO
Will Glooko go IPO?
Glooko has not yet filed for an IPO. However, it’s important to note that IPOs are not the sole avenue for a private company to transition to public trading. Private companies can also go public through alternative methods such as but limited to Special Purpose Acquisition Companies (SPACs), direct listings, or mergers and acquisitions. Find out which companies are eyeing an IPO on our Tech IPO Calendar 2025.
What is Glooko’s IPO price?
The Glooko IPO price does not exist at this time, as Glooko is still a private company and has not yet conducted an IPO. To explore secondary market data and access private market pricing details and data that may be related to Glooko, register for Forge today.
When was Glooko founded?
Glooko was founded in 2010.
What is Glooko funding to date?
Glooko has raised $521.83MM to date.
Glooko major investors
Canaan Partners
Georgian
Health Catalyst Capital Management
Insulet
Mayo Clinic
Medtronic
Novo Nordisk
Realization Capital Partners
Samsung Next Ventures
Social Capital
Xtreme Labs
Show All InvestorsShow Fewer Investors
Glooko pre-IPO valuation and funding rounds
Funding history chart
Funding round and deals details
Funding Date
Round
Amount Raised
Price per Share
Post-Money Valuation 3
Key Investors
10/10/2024
Series F
$100MM
$2.42
$475.64MM
Canaan, Georgian Partners, Health Catalyst Capital
Price per Share
$ xx.xx
Shares Outstanding
41,407,867
Liquidation Pref Order
1
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan, Georgian Partners, Health Catalyst Capital
08/18/2023
Series E
$30.56MM
$2.42
$318.34MM
Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
12,652,982
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
08/18/2023
Series E-Prime
$30.56MM
$2.42
$318.34MM
Undisclosed Investors
Price per Share
$ xx.xx
Shares Outstanding
12,652,982
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors
03/16/2021
Series D
$20MM
$1.33
$150.67MM
Canaan Partners, Georgian, Health Catalyst Capital, Insulet, Mayo Clinic, Novo Nordisk
Price per Share
$ xx.xx
Shares Outstanding
15,021,772
Liquidation Pref Order
3
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Georgian, Health Catalyst Capital, Insulet, Mayo Clinic, Novo Nordisk
03/16/2021
Series D-Prime
$10MM
$1.33
$150.67MM
Canaan Partners, Georgian, Health Catalyst Capital, Insulet, Mayo Clinic, Novo Nordisk
Price per Share
$ xx.xx
Shares Outstanding
7,510,886
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Georgian, Health Catalyst Capital, Insulet, Mayo Clinic, Novo Nordisk
06/27/2017
Series C-1
$13.29MM
$1.26
$116.76MM
Canaan Partners, Georgian Partners, Insulet, Mayo Clinic, Medtronic, Samsung, Social Capital
Price per Share
$ xx.xx
Shares Outstanding
10,562,032
Liquidation Pref Order
4
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Georgian Partners, Insulet, Mayo Clinic, Medtronic, Samsung, Social Capital
06/27/2017
Series C-1-Prime
$13.01MM
$1.26
$116.76MM
Canaan Partners, Georgian Partners, Insulet, Mayo Clinic, Medtronic, Samsung, Social Capital
Price per Share
$ xx.xx
Shares Outstanding
10,335,930
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Georgian Partners, Insulet, Mayo Clinic, Medtronic, Samsung, Social Capital
09/17/2016
Series C
$8.35MM
$2.02
$135.3MM
Canaan Partners, Samsung, Social Capital, Yogen Dalal
Price per Share
$ xx.xx
Shares Outstanding
4,130,876
Liquidation Pref Order
5
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Samsung, Social Capital, Yogen Dalal
09/17/2016
Series C-Prime
$8.35MM
$2.02
$135.3MM
Canaan Partners, Samsung, Social Capital, Yogen Dalal
Price per Share
$ xx.xx
Shares Outstanding
4,130,876
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Samsung, Social Capital, Yogen Dalal
03/17/2015
Series B
$8.25MM
$1.36
$85.02MM
Canaan Partners, Medtronic, Samsung, Social Capital
Price per Share
$ xx.xx
Shares Outstanding
6,061,808
Liquidation Pref Order
6
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Medtronic, Samsung, Social Capital
03/17/2015
Series B-Prime
$8.25MM
$1.36
$85.02MM
Canaan Partners, Medtronic, Samsung, Social Capital
Price per Share
$ xx.xx
Shares Outstanding
6,061,808
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Canaan Partners, Medtronic, Samsung, Social Capital
01/08/2014
Series A-1
$3.5MM
$0.78
$25.22MM
Lifeforce Ventures, Samsung, Social Capital, Sundeep Madra, Yogen Dalal
Price per Share
$ xx.xx
Shares Outstanding
4,504,968
Liquidation Pref Order
7
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Lifeforce Ventures, Samsung, Social Capital, Sundeep Madra, Yogen Dalal
01/08/2014
Series A-1-Prime
$3.5MM
$0.78
$25.22MM
Lifeforce Ventures, Samsung, Social Capital, Sundeep Madra, Yogen Dalal
Price per Share
$ xx.xx
Shares Outstanding
4,504,968
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
1.0x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Lifeforce Ventures, Samsung, Social Capital, Sundeep Madra, Yogen Dalal
01/30/2012
Series A
$1.15MM
$10.00
$29.2MM
Andy Hertzfeld, Bill Campbell, Judy Estrin, Russell Hirsch, Social Capital, Venky Harinarayan, Vint Cerf, Xtreme Labs
Price per Share
$ xx.xx
Shares Outstanding
115,000
Liquidation Pref Order
8
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
5.6x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andy Hertzfeld, Bill Campbell, Judy Estrin, Russell Hirsch, Social Capital, Venky Harinarayan, Vint Cerf, Xtreme Labs
01/30/2012
Series A-Prime
$1.15MM
$10.00
$29.2MM
Andy Hertzfeld, Bill Campbell, Judy Estrin, Russell Hirsch, Social Capital, Venky Harinarayan, Vint Cerf, Xtreme Labs
Price per Share
$ xx.xx
Shares Outstanding
115,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
5.6x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andy Hertzfeld, Bill Campbell, Judy Estrin, Russell Hirsch, Social Capital, Venky Harinarayan, Vint Cerf, Xtreme Labs
11/09/2011
Series Seed
$500,000.00
$2.00
$5MM
Anand Agarawala, Andy Hertzfeld, Bill Campbell, Judy Estrin, Russel Hirsch, Social Capital, Venky Harinarayan and Annad Rajaraman, Vint Cerf, Xtreme Labs
Price per Share
$ xx.xx
Shares Outstanding
250,000
Liquidation Pref Order
8
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
2.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Anand Agarawala, Andy Hertzfeld, Bill Campbell, Judy Estrin, Russel Hirsch, Social Capital, Venky Harinarayan and Annad Rajaraman, Vint Cerf, Xtreme Labs
11/09/2011
Series Seed-Prime
$500,000.00
$2.00
$5MM
Anand Agarawala, Andy Hertzfeld, Bill Campbell, Judy Estrin, Russel Hirsch, Social Capital, Venky Harinarayan and Annad Rajaraman, Vint Cerf, Xtreme Labs
Price per Share
$ xx.xx
Shares Outstanding
250,000
Liquidation Pref Order
2
Liquidation Pref As Multiplier
2.0x
Conversion Ratio
2.1x
Dividend Rate
8.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Anand Agarawala, Andy Hertzfeld, Bill Campbell, Judy Estrin, Russel Hirsch, Social Capital, Venky Harinarayan and Annad Rajaraman, Vint Cerf, Xtreme Labs
Glooko, Inc., a global integrated digital health company connecting patients, providers, biopharma and medical device partners, today announced that it has secured a $100 million Series F financing. The Company’s Board of Directors also announced the appointment of Mike Alvarez as Chief Executive Officer. The financing round, led by Georgian, with investments from Health Catalyst Capital, Canaan and other investors and business partners, will support Glooko’s continued growth and product expansion in expert data insights, device integrations, clinical research and chronic condition support for healthcare providers around the world.
Diabetes management firm Glooko is partnering with Denmark-based Hedia to incorporate its app into Glooko's remote monitoring platform. The Hedia Diabetes Assistant app, which gives bolus insulin dosing advice, will sync with Glooko's platform, allowing patients to share their diabetes data with healthcare providers. The integration is expected to launch in Europe in Q4 2023 and Q1 2024.
Glooko and Sanofi have partnered to incorporate a connected device for insulin pens into Glooko's digital platform. The SoloSmart device works with Sanofi’s insulin injection pens and records the insulin dose, date and time of injection. This data can then be visualised on the Glooko app and shared with healthcare professionals for improved diabetes management. Sanofi plans to utilise Glooko's global presence in over 8,000 clinics to increase digital solutions accessibility. SoloSmart is not yet approved for marketing in the U.S.
Track trading activity and investor momentum across thousands of private companies. Register to view last matched prices and additional transactional details.
Forge, your trusted partner for pre-IPO insights and Glooko data
Forge is the trusted platform for buying and selling pre-IPO shares. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.
PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES
Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
Market activity indicates the level of activity for a company based on recent IOIs, secondary transactions, and pending transactions on Forge.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
Actively traded companies are companies with a high market activity with the highest post-money valuation in the same sector.
‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.
The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.
Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.
PRIVATE MARKET UPDATE
